Company Overview and News
Small caps have outperformed large caps YTD, with the iShares Russell 2000 ETF (IWM) up nearly 7% compared to less than 3% for the SPY. Most of the outperformance has come in recent weeks and can be attributed in part to the trade war rhetoric. While the current status of the trade war is 'on hold', there's plenty of reasons to believe we are still in the early innings of trade negotiations. Investing in some small cap companies that are less exposed to foreign tariffs could be a winning strategy for the foreseeable future.
ESXB EVH CARO CHGG IWM
Small cap stocks record fresh all-time highs leading the broader market indexes higher for the first time in a couple of years.
NKTR FB ECYT GTHX GES NFLX CHGG NVDA CRZO TWLO IMMU AAPL HRTX ENVA CRSP SRPT FOSL SFLY I CBIO GOOGL MRTX TRI MSFT
Chegg, Inc. (CHGG - Free Report) has acquired the Berkeley-based startup, WriteLab, Inc. The buyout has strengthened its writing services with new tools, features and functionality. The all-cash transaction is valued at about $15 million. Chegg will likely make an additional payment of $5 million to key employees over the next three years, either in cash or stock, provided the key employees continue their employment.
APPF TWTR WDAY CHGG
Risk appetite remains positive with small caps demonstrating resilience throughout the consolidation phase, and model portfolios recording double-digit gains.
ECYT GTHX GES CRSP CHGG FOSL SFLY I QCP CBIO TWLO IMMU NDAQ MRTX HRTX ENVA
Chegg, Inc.’s (CHGG - Free Report) first quarter 2018 adjusted earnings of 1 cents per share was in line with the Zacks Consensus Estimate and increased substantially from the prior-year quarter’s loss of 3 cents. The upside can be attributed to increased investments behind new subjects, content, formats and services. Net revenues of $76.9 million surpassed the consensus estimate of $74.4 million by 3.
NICE NCSYF TWTR VEEV SAH CHGG
Greetings, and welcome to the Chegg First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation [Operator Instructions]. As a reminder, this conference is being recorded.
12h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
13h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET